Wendy I. White

机构：AstraZeneca (United States) · ORCID：0000-0002-3286-0043

发表论文 73 篇 · 总被引 4924 次 · h-index 33

代表论文

• Eosinophil Depletion with Benralizumab for Eosinophilic Esophagitis (2024 · New England Journal of Medicine · 被引 104)
• Modulation of Cardiometabolic Disease Markers by Type I Interferon Inhibition in Systemic Lupus Erythematosus (2020 · Arthritis & Rheumatology · 被引 75)
• Type I interferon receptor blockade with anifrolumab corrects innate and adaptive immune perturbations of SLE (2018 · Lupus Science & Medicine · 被引 74)
• Type I interferon blockade with anifrolumab in patients with systemic lupus erythematosus modulates key immunopathological pathways in a gene expression and proteomic analysis of two phase 3 trials (2024 · Annals of the Rheumatic Diseases · 被引 71)
• Benralizumab in children with severe eosinophilic asthma: Pharmacokinetics and long‐term safety ( TATE study) (2024 · Pediatric Allergy and Immunology · 被引 33)
• Pharmacodynamic biomarkers and differential effects of TNF ‐ and GM ‐ CSF ‐targeting biologics in rheumatoid arthritis (2018 · International Journal of Rheumatic Diseases · 被引 32)